MIAMI, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today that it has been included in the 2021 Psychedelic Investor Guide.
The Psychedelic Investor Guide covers biotechnology, pharmaceutical and life sciences companies that are leading the emerging psychedelics medicine industry.
Ben Kaplan, Ehave President and CEO stated, “Ehave’s inclusion in the Psychedelic Investor Guide is further validation of our strategy of integrating digital therapeutics with psychedelic medicine to improve mental health and increase productivity. Ehave is proud to be recognized as one of the leaders in this emerging space and our inclusion in the Guide will increase investor awareness to the Company’s progress, as we launch a number of our most important initiatives.”
Roland Rick Perry, President of Institutional Analyst, publisher of the guide and Editor of the Psychedelic Stock Review stated, “It’s exciting to read about companies like Ehave and their ambitious development plans. The emergence of the sector reminds us of the emergence of the Internet sector when we first launched the Internet Stock Review in 1998. The Guide, in PDF, was formatted to provide an easy and quick way for investors to literally flip page after page, looking for investment opportunities in the sector – from the small to the large. Nobody guessed Amazon would grow to be the Amazon it is today, and we are excited to be early to this sector. We feel confident many of the Companies in the Guide will go on to great success, improving lives and greatly benefiting the early shareholders over the coming decade.”
Investors can find additional information on the 2021 Psychedelic Investor Guide on the Psychedelic Stock Review website at Psychedelic Investor Guide.
About the 2021 Psychedelic Investor Guide
The Psychedelic Investor Guide is the most comprehensive and easy to use guide covering the Psychedelic sector. Up to 46 of the top companies are listed with charts, basic financial information, basic business description, and the six most recent headlines, with links to the press releases. Also included are direct links to each Company’s investor relations page and a direct link to their SEC or Sedar filings page. Everything an investor needs to get acquainted with the emerging leaders.
Institutional Analyst Inc., (IA) is an independent investment research firm. IA is a leading publisher of news, perspective, and market intelligence reports on the equity markets. IA’s investor relations division utilizes the research to introduce small and microcap companies - to professional investors including investment brokers, small cap mutual funds, private investment managers and hedge fund managers.
For further information or to have your Psychedelic Company be considered for inclusion, contact Roland Rick Perry @ 310-594-8062 or Roland@InstitutionalAnalyst.com.
About Ehave Inc.
Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes meeting privacy and HIPAA & GDPR Compliant. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. The Ehave dashboard offers Offline Encrypted Digital Records Empowering Healthcare providers and patients and it's a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.
For Investors Relations, please contact:
Gabe Rodriguez
Phone: (623) 261-9046
Email: ir@ehave.com
